Janus Henderson Group
SPRY icon

Janus Henderson Group’s ARS Pharmaceuticals SPRY Stock Holding History

Janus Henderson Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$174K Hold
21,600
– – ﹤0.01% 2350
2025
Q4 		$252K Hold
21,600
– – ﹤0.01% 2278
2025
Q3 		$217K Sell
21,600
-47,879
-69% -$687K ﹤0.01% 2315
2025
Q2 		$1.21M Buy
69,479
+47,879
+222% +$691K ﹤0.01% 1521
2025
Q1 		$270K Hold
21,600
– – ﹤0.01% 2249
2024
Q4 		$228K Hold
21,600
– – ﹤0.01% 2374
2024
Q3 		$313K Hold
21,600
– – ﹤0.01% 2246
2024
Q2 		$183K Sell
21,600
-213
-1% -$1.89K ﹤0.01% 2415
2024
Q1 		$223K Buy
21,813
+4
+0% +$30 ﹤0.01% 2375
2023
Q4 		$120K Sell
21,809
-74
-0.3% -$324 ﹤0.01% 2513
2023
Q3 		$82.9K Buy
21,883
+4
+0% +$26 ﹤0.01% 2533
2023
Q2 		$147K Buy
+21,879
New +$146K ﹤0.01% 2522

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group's SPRY Position: Q1 2026 in Review

Janus Henderson Group held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 21,600 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #2350.

Janus Henderson Group first reported a position in SPRY in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.21M in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Janus Henderson Group held 21,600 shares of ARS Pharmaceuticals worth $174K as of Q1 2026.
  • Janus Henderson Group left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #2350 holding.
  • Janus Henderson Group first reported a position in ARS Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Janus Henderson Group's ARS Pharmaceuticals position peaked at $1.21M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.